Prediction of overall survival for metastatic pancreatic cancer: Development and validation of a prognostic nomogram with data from open clinical trial and real‐world study-Reference-Cited by-同舟云学术

Prediction of overall survival for metastatic pancreatic cancer: Development and validation of a prognostic nomogram with data from open clinical trial and real‐world study

Published:2018-06 Issue:7 Volume:7 Page:2974-2984
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Hang Junjie¹^ORCID,Wu Lixia²,Zhu Lina¹,Sun Zhiqiang¹,Wang Ge¹,Pan Jingjing¹,Zheng Suhua¹,Xu Kequn¹,Du Jiadi³,Jiang Hua¹

Affiliation:

1. Department of Oncology Changzhou No.2 People's Hospital the Affiliated Hospital of Nanjing Medical University Changzhou China

2. Department of Oncology Shanghai JingAn District ZhaBei Central Hospital Shanghai China

3. Center of Data Mining and Business Analytics Rutgers Business School Newark NJ USA

Funder

Changzhou Science and Technology Bureau

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.1573

Reference33 articles.

1. Global cancer statistics, 2012

2. Cancer statistics in China, 2015

3. Pancreatic cancer

4. Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages

5. Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer;The Oncologist;2024-05-04

2. Precision medicine for KRAS wild-type pancreatic adenocarcinomas;European Journal of Cancer;2024-01

3. Isolated pulmonary metastases in pancreatic ductal adenocarcinoma: a review of current evidence;Cancer Biology & Therapy;2023-08

4. C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel;Scientific Reports;2023-05-31

5. Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON study;International Journal of Clinical Oncology;2023-05-20